WebMD: Awiqli: FDA Approves First and Only Once-Weekly Long-Acting Basal Insulin for Adults With Type 2 Diabetes The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers convenient weekly dosing compared with daily basal insulin injections. Awiqli: FDA Approves First and Only Once-Weekly Long-Acting Basal Insulin for Adults With Type 2 Diabetes The American Journal of Managed Care: AI Matches Physician Accuracy in Insulin Dosing for T2D Artificial intelligence (AI) can match physician insulin dosing, maintaining target blood sugar levels in patients with type 2 diabetes. A study showed an AI-based insulin decision support system's ...
Healio: FDA approves once-weekly basal insulin for adults with type 2 diabetes The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal insulin, Novo Nordisk announced. Insulin icodec-abae (Awiqli, Novo Nordisk) ... Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
